BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/16/2014 6:10:00 PM | Browse: 1442 | Download: 1420
 |
Received |
|
2012-08-05 17:03 |
|
Peer-Review Started |
|
2012-09-03 16:46 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2012-11-05 08:19 |
|
Revised |
|
2012-11-05 19:34 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2012-12-27 09:32 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2012-12-27 13:41 |
|
Articles in Press |
|
|
|
Edit the Manuscript by Language Editor |
|
2013-01-09 17:07 |
|
Typeset the Manuscript |
|
2013-01-30 17:06 |
|
Publish the Manuscript Online |
|
2013-02-06 11:36 |
| Category |
Oncology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
De-Bang Li, Feng Ye, Xiu-Rong Wu, Lu-Peng Wu, Jing-Xi Chen, Bin Li and Yan-Ming Zhou |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yan-Ming Zhou, MD, Department of Hepatobiliary and Pancreatovascular Surgery, First Affiliated Hospital of Xiamen University, Oncologic Center of Xiamen, 55 Zhenhai Road, Xiamen 361003, Fujian Province, China. zhouyms@yahoo.com.cn |
| Key Words |
Colorectal cancer; Liver metastases; Bevacizumab; Postoperative complication; Sinusoidal dilatation |
| Core Tip |
|
| Publish Date |
2013-02-06 11:36 |
| Citation |
Li DB, Ye F, Wu XR, Wu LP, Chen JX, Li B, Zhou YM. Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases. World J Gastroenterol 2013; 19(5): 761-768 |
| URL |
http://www.wjgnet.com/1007-9327/full/v19/i5/761.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v19.i5.761 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
